Louis Navellier’s 10 New Stock Picks

7. ADMA Biologics, Inc. (NASDAQ:ADMA)

Number of Hedge Fund Holders as of Q4: 37

Navellier & Associates’ Equity Stake: $3.06 Million

ADMA Biologics, Inc. (NASDAQ:ADMA) is a fully integrated commercial biopharmaceutical company specializing in the development, manufacturing, and marketing of specialty biologics aimed at treating immunodeficient patients and others at heightened risk for certain infectious diseases. The company’s portfolio and operations are focused on providing essential therapies to vulnerable patient populations who require immune support to combat serious infections.

In the fourth quarter of 2024, ADMA Biologics, Inc. (NASDAQ:ADMA) reported exceptionally strong financial results, significantly outperforming market expectations. The company achieved earnings per share (EPS) of $0.46, as compared to the forecasted $0.15, exceeding expectations by over 300%. Revenue for the quarter also surpassed projections, totaling $117.5 million compared to the anticipated $113.4 million. This impressive performance represented a 59% year-over-year increase in quarterly revenue, reflecting the company’s accelerating growth trajectory.

Over the full year of 2024, ADMA Biologics, Inc. (NASDAQ:ADMA) continued this momentum, reporting total revenue of $426.5 million, which demonstrated a substantial 65% increase from the prior year. The company’s financial turnaround was particularly noteworthy, as it recorded a net income of $197.7 million for the year, as opposed to a net loss of $28.2 million in 2023. This shift from losses to profitability underscores the success of ADMA’s strategic initiatives and expanding market demand for its specialized products.

ADMA Biologics, Inc. (NASDAQ:ADMA) is one of Louis Navellier’s new stock picks. During the December quarter in 2024, Navellier & Associates invested over $3 million in the company, purchasing 178,745 shares. Hedge fund sentiment also increased; according to Insider Monkey’s database, 37 hedge funds held shares in the company by the end of Q4 with a combined stake of $436.9 million, significantly up from 25 funds in Q3.

Looking ahead, ADMA Biologics, Inc. (NASDAQ:ADMA) has established ambitious financial goals for the coming years. For 2025, the company aims to achieve revenue exceeding $490 million and an adjusted EBITDA of more than $225 million, continuing its aggressive growth strategy. Furthermore, ADMA projects even greater expansion in 2026, targeting revenue in excess of $650 million, reflecting confidence in its business model, market opportunities, and operational execution.